# US 2025/0367258 A1 · IL-10-Producing CD4+ T Cells and Uses Thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0367258 A1
- Document ID: US20250367258A1
- Status: Published application
- Kind: A1
- Application number: 19/062,832
- Filed: 2025-02-25
- Published: 2025-12-04
- Earliest claimed: 2015-03-13
- Assignees: Fondazione Telethon; Ospedale San Raffaele S.R.L.; Fondazione Centro San Raffaele
- Applicants: Fondazione Telethon; Ospedale San Raffaele Srl; Fondazione Centro San Raffaele
- Inventors: Silvia Adriana GREGORI; Maria Grazia RONCAROLO
- Web page: https://patentgrep.com/patent/US20250367258A1

## CPC

- A61K 38/2066: {IL-10}
- A61K 40/10: characterised by the cell type used
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/22: Immunosuppressive or immunotolerising
- A61K 40/418: {Antigens related to induction of tolerance to non-self}
- A61K 40/42: Cancer antigens
- A61P 35/00: Antineoplastic agents
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- G01N 33/5759: {involving compounds localised on the membrane of tumour or cancer cells}
- A61K 40/50: characterised by the use of allogeneic cells
- A61K 2239/31: characterized by the route of administration
- A61K 2239/38: characterised by the dose, timing or administration schedule
- A61K 2239/48: Blood cells, e.g. leukemia or lymphoma
- G01N 2333/70525: ICAM molecules, e.g. CD50, CD54, CD102
- G01N 2333/70539: MHC-molecules, e.g. HLA-molecules
- G01N 2333/70596: Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to a CD4+ T cell that produces high levels of IL-10 for use in the treatment and/or prevention of a tumor that expresses CD13, HLA-class I and CD54 and/or for use in inducing Graft versus tumour (GvT). The present invention relates also to a composition comprising said cell and to a method to select a subject to be treated with said cell.

## Claims

### Claim 1

(canceled)

### Claim at position 2

2-26. (canceled)

### Claim 27

A method of treating a human subject having a hematological cancer that expresses CD13, HLA-class I, and CD54, the method comprising:
administering to the subject
(a) allogeneic-hematopoietic stem cell transplant (allo-HSCT), and
(b) human CD4+ T cells that have been genetically modified to comprise the coding sequence of human IL-10 under control of a constitutive promoter, wherein the genetically modified CD4+ T cells produce increased levels of human IL-10 compared to unmodified CD4+ T cells,
wherein the genetically modified CD4+ T cells are not from the allo-HSCT donor and have not been anergized to subject (host) antigens in vitro, and
wherein the genetically modified CD4+ T cells are administered in an amount sufficient to suppress the growth of the hematological cancer and to inhibit Graft vs Host Disease in the subject.

### Claim 28 (depends on 27)

The method of claim 27, wherein the hematological cancer is selected from the group consisting of: acute lymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myelomonocytic leukemia, chronic myelogenous leukemia, multiple myeloma, and myelodysplastic syndrome.

### Claim 29 (depends on 27)

The method of claim 27, wherein the hematological cancer is relapsed or refractory.

### Claim 30 (depends on 27)

The method of claim 27, further comprising administering an additional therapy to the subject.

### Claim 31 (depends on 30)

The method of claim 30, wherein the additional therapy is selected from the group consisting of: chemotherapy, radiotherapy, blood transfusion, and blood marrow transplant.

### Claim 32 (depends on 27)

The method of claim 27, wherein the hematological cancer further expresses CD112.

### Claim 33 (depends on 27)

The method of claim 27, wherein 104 to 108 cells/kg of the genetically modified CD4+ T cells are administered to the subject.

### Claim 34 (depends on 27)

The method of claim 27, wherein 106 cells/kg of the genetically modified CD4+ T cells are administered to the subject.

### Claim 35 (depends on 27)

The method of claim 27, wherein the genetically modified CD4+ T cells kill myeloid cells.

### Claim 36 (depends on 35)

The method of claim 35, wherein the myeloid cells are CD13+ myeloid cells.

### Claim 37 (depends on 35)

The method of claim 35, wherein the myeloid cells are CD14+ myeloid cells.

### Claim 38 (depends on 27)

The method of claim 27, wherein the genetically modified CD4+ T cells are administered to the subject every day, every 7 days, every 14 days, every 21 days, or every month.
